By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – StemCells Inc. today announced that it will raise $5.7 million through a private placement of its common stock with Seaside 88, a private investment limited partnership.

The Palo Alto, Calif.-based firm said that it will sell 7 million shares to Seaside 88 at a price of $.865 per share, representing a 12.6 percent discount to its closing price on June 29. The company expects to close the deal today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

In Genome Biology this week: miRNAs linked to diffuse large B-cell lymphoma outcomes, database of bird genomes, and more.